KyungdongPharm
Financials
Valuation Metrics
KyungdongPharm's Market Cap is ₩1520B. At end of 2025 it was ₩1797B. Ranked #967 of 2,436 in KR market (top 40%), #467 of 1,649 on KOSDAQ (top 28%), #111 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 47%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 152.00B KRW | KR#967/2,436 Sec#111/234 |
| Revenue | 198.27B KRW | KR#1,024/2,436 Sec#61/234 |
| Net Income | 11.55B KRW | KR#855/2,436 Sec#54/234 |
| Total Assets | 309.30B KRW | KR#1,003/2,436 Sec#69/234 |
| Net Assets | 229.60B KRW | KR#851/2,436 Sec#58/234 |
| Employees | 383 | KR#635/2,436 Sec#55/234 |
| Value | ||
| P/E | 13.16x | KR#896/2,436 Sec#55/234 |
| P/B | 0.66x | KR#1,113/2,436 Sec#57/234 |
| PEG | 0.07x | KR#327/2,436 Sec#17/234 |
| P/S | 0.77x | KR#1,230/2,436 Sec#64/234 |
| EV/EBITDA | 18.91x | KR#988/2,436 Sec#58/234 |
| FCF Yield | -0.96% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 5.03% | KR#997/2,436 Sec#75/234 |
| ROA | 3.73% | KR#832/2,436 Sec#74/234 |
| Op. Margin | 4.31% | KR#1,010/2,436 Sec#78/234 |
| Revenue Growth | 4.37% | KR#1,197/2,436 Sec#113/234 |
| Earnings Growth | 190.63% | KR#255/2,436 Sec#17/234 |
| Financial Health | ||
| Debt Ratio | 134.71% | KR#939/2,436 Sec#109/234 |
| Total Debt | 25.26B KRW | KR#1,274/2,436 Sec#103/234 |
| FCF | -1.46B KRW | KR#1,306/2,436 Sec#101/234 |
| Cash | 15.61B KRW | KR#1,393/2,436 Sec#105/234 |
| Current Ratio | 1.63x | KR#1,207/2,436 Sec#133/234 |
| Net Debt/EBITDA | 1.13x | KR#810/2,436 Sec#55/234 |
| Dividend | ||
| Div. Yield | 6.12% | KR#172/2,436 Sec#5/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -16.97% | KR#1,138/2,436 Sec#86/234 |
| 1M Return | -0.80% | KR#807/2,436 Sec#60/234 |
| From 52W High | -28.30% | KR#353/2,436 Sec#23/234 |
| 1Y MDD | -23.87% | KR#90/2,436 Sec#5/234 |
| Trading | ||
| Volume | 17,422 shares | KR#1,818/2,436 Sec#173/234 |
| Foreign Own. | 1.81% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 378 KRW | KR#1,029/2,436 Sec#71/234 |
| BPS | 8,240 KRW | KR#1,061/2,436 Sec#75/234 |
Company Info
Kyungdong Pharm, established in 1976, manufactures and sells pharmaceuticals, specializing in professional medications like circulatory and digestive system agents, and antihypertensive drugs, including products such as Duoroban Tablets and Alfortin Soft Capsules. The company boasts state-of-the-art solid formulation and injectable manufacturing facilities that meet EU-GMP and US c-GMP standards. Leveraging proprietary raw material synthesis and formulation technologies, it achieves continuous revenue growth through combination drug development, increased investment in biotech firms, and the launch of its WIAVIM health functional food brand.